Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure ...
Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...
Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a ...
WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
Jim Exon, a Democrat who served two terms as governor and three terms in the U.S. Senate for Nebraska, died Friday. He was 83. Exon died of natural causes at Madonna Rehabilitation Hospital, his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results